Fundraising Fox
Trovagene
NASDAQ: CRDFSan Diego, US · Founded 1999 · Delaware corporation · 51 employees on LinkedIn · 2 known investors
Find your way into Trovagene
Each arrow is one introduction. Sign up to fill in the first one.
128 people can intro you to David
Ask Chris Rausch to introduce you to David Robbins
You →Chris · together at Quest Diagnostics →David
Sign up to find every way you can get introduced to Trovagene
- Your email: who you already know at Trovagene, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Trovagene team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Trovagene is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor, for treatment of cancers including RAS-mutated metastatic colorectal cancer, pancreatic cancer, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia, with the goal of combining it with standard chemotherapy agents to improve patient outcomes.
Founders & leadership
TA
Thomas AdamsExecutive
DR
David RobbinsVice President, Research2006–2012David Robbins is Executive Officer of Trovagene, a clinical-stage biotechnology company developing onvansertib for treatment of multiple cancer types. He has expertise in immunoassays, PCR methods, microarray analysis, and DNA sequencing, with experience spanning basic research, development, clinical trial design, and regulatory submissions.
SZ
Steve ZanibobiExecutive
Board
GC
Gabriele CerroneBoard director
GJ
Gary JacobBoard director
JB
John BrancaccioBoard director
AC
Athena CountouriotisBoard director
RM
Rodney MarkinBoard director
ST
Stanley TennantBoard director
Investors · 2
ACORN BIOVENTURESreportedNew York
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
Lincoln Park Capital Fund, LLC
Reported raises · per SEC filings
Form D private placements$35M disclosed across 9 of 10 rounds · 2009–2020
▶$13.5MraisedJun 2020 · 3 investors · BiotechnologyRule 506(b)
▶$13.5MraisedJun 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary JacobDirector
- Mark ErlanderExecutive Officer, Director
- James O. ArmitageDirector
- Lale WhiteDirector
- Thomas AdamsDirector
- Rodney S. MarkinDirector
- John BrancaccioDirector
- Gary W. PaceDirector
- Offering amount
- $13.5M
- Amount sold
- $13.5M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedJun 2020 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJun 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary JacobDirector
- Thomas AdamsDirector
- John BrancaccioDirector
- Lale WhiteDirector
- Mark ErlanderExecutive Officer
- Gary W. PaceDirector
- Rodney S. MarkinDirector
- James O. ArmitageDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$810KraisedMay 2020 · 8 investors · BiotechnologyRule 506(b)
▶$810KraisedMay 2020 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Adams, Ph.D.Director
- Rodney MarkinDirector
- Mark Erlander, Ph.D.Executive Officer
- James ArmitageDirector
- Gary Jacob, Ph.D.Director
- Gary Pace, Ph.D.Director
- John BrancaccioDirector
- Lale WhiteDirector
- Offering amount
- $810K
- Amount sold
- $810K
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedApr 2020 · 1 investors · BiotechnologyRule 506(b)
▶$2.1MraisedApr 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rodney S. MarkinDirector
- Mark ErlanderDirector
- Thomas AdamsExecutive Officer, Director
- John BrancaccioDirector
- James O. ArmitageDirector
- Lale WhiteDirector
- Gary W. PaceDirector
- Gary JacobDirector
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedOct 2019 · 2 investors · BiotechnologyRule 506(b)
▶$5MraisedOct 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Athena CountouriotisDirector
- Brigitte LindsayExecutive Officer
- Rodney MarkinDirector
- Gary S. JacobDirector
- Thomas H. AdamsExecutive Officer, Director
- John P. BrancaccioDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Sales commissions
- $1.1M
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedAug 2019 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedAug 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Athena CountouriotisDirector
- John BrancaccioDirector
- Rodney S. MarkinDirector
- Gary JacobDirector
- Thomas AdamsExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMay 2019 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedMay 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rodney S. MarkinDirector
- Athena CountouriotisDirector
- Gary JacobDirector
- John BrancaccioDirector
- Thomas AdamsExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedApr 2019 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedApr 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary JacobDirector
- Thomas AdamsExecutive Officer, Director
- John BrancaccioDirector
- Athena CountouriotisDirector
- Rodney S. MarkinDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Trovagene do?
- Trovagene is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor, for treatment of cancers including RAS-mutated metastatic colorectal cancer, pancreatic cancer, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia, with the goal of combining it with standard chemotherapy agents to improve patient outcomes.
- Who are Trovagene's investors?
- Trovagene's investors include ACORN BIOVENTURES.
- How much funding has Trovagene raised?
- Trovagene has disclosed $35M raised across 9 of its 10 known rounds.
- Where is Trovagene headquartered?
- Trovagene is headquartered in San Diego, US.